Impact of elexacaftor/tezacaftor/ivacaftor on depression and anxiety in cystic fibrosis

BACKGROUND: Cystic fibrosis (CF) is associated with worsening of depression and anxiety symptoms. Elexacaftor/tezacaftor/ivacaftor (Trikafta®), a cystic fibrosis transmembrane regulator (CFTR) modulator approved in 2019, significantly improves lung function, decreases pulmonary exacerbations, and im...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Lijia, Albon, Dana, Jones, Marieke, Bruschwein, Heather
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793010/
https://www.ncbi.nlm.nih.gov/pubmed/36562554
http://dx.doi.org/10.1177/17534666221144211

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793010/
https://www.ncbi.nlm.nih.gov/pubmed/36562554
http://dx.doi.org/10.1177/17534666221144211

Ejemplares similares